This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mesa Labs (MLAB) Q2 Earnings Top Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 0.58% and -1.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs (MLAB) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 7.18% and 2.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Mesa Labs (MLAB) Q1 Earnings Expected to Decline
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs (MLAB) Misses Q3 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -1.08% and 3.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session
by Zacks Equity Research
Neovasc (NVCN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Edwards Lifesciences (EW) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Edwards Lifesciences (EW) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Mesa Laboratories (MLAB) Enters Oversold Territory
by Zacks Equity Research
Mesa Laboratories, Inc. (MLAB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Mesa Laboratories Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Mesa Laboratories has been struggling lately, but the selling pressure may be coming to an end soon.
New Strong Sell Stocks for November 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
The Zacks Analyst Blog Highlights: PRA Health Sciences, Mesa Laboratories, ConforMIS, Check-Cap and Streamline Health Solutions
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PRA Health Sciences, Mesa Laboratories, ConforMIS, Check-Cap and Streamline Health Solutions
5 MedTech Stocks to Buy Before Q3 Earnings
by Zacks Equity Research
The Q3 earnings season is just around the corner for the political hotspot MedTech space.
5 Medtech Stocks to Steer Clear of Amid Political Chaos
by Zacks Equity Research
In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.
Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.
VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.
IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues
by Zacks Equity Research
Hill-Rom Holdings (HRC) rides high on international growth and product innovation.
NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.
Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.
GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates
by Zacks Equity Research
Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).
Align Technology (ALGN) Beats on Q2 Earnings and Revenues
by Zacks Equity Research
Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.
QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View
by Zacks Equity Research
QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.